Phaseline

Targets › OCN19

OCN19: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout Dec 2028.

Open in Phaseline: the race on OCN19, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Lu jin ,MDmesenchymal stem cells with OCN-19
OCN19-overexpressed mesenchymal stem cells that stimulate insulin gene expression and isle
OCN19Phase 2DiabetesDec 2028

Conditions

Diabetes (1)

Modalities

mixed (1)

Companies

Lu jin ,MD (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.